AstraZeneca

AstraZeneca Tangible Book Value per Share

The Tangible Book Value per Share of AstraZeneca (AZN.L) as of Nov 20, 2026 is -6.67 USD. In the previous year, Tangible Book Value per Share was -11.15 USD — a change of -40.16% (higher).

Tangible Book Value per Share

-6.67USD

YoY

-40.16%

Last updated:

Tangible Book Value per Share of AstraZeneca is 2025 -6.67 USD. Tangible Book Value per Share of AstraZeneca was 2024 -11.15 USD. It decreases by -40.16% higher compared to the previous year.

The AstraZeneca Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
-13.57 USD
Jan 1, 2019
-12.16 USD
Jan 1, 2020
-10.99 USD
Jan 1, 2021
-14.80 USD
Jan 1, 2022
-14.14 USD
Jan 1, 2023
-12.05 USD
Jan 1, 2024
-11.15 USD
Jan 1, 2025
-6.67 USD
The AstraZeneca Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
-6.67USD-40.16%
-11.15USD-7.48%
-12.05USD-14.78%
-14.14USD-4.44%
-14.80USD+34.63%
-10.99USD-9.61%
-12.16USD-10.39%
-13.57USD-8.05%
-14.76USD-5.48%
-15.61USD+52.21%
-10.26USD+24.18%
-8.26USD+270.39%
-2.23USD+6.34%
-2.10USD-212.75%
1.86USD+121.37%
0.84USD-183.80%
-1.00USD-76.90%
-4.34USD-3.75%
-4.51USD-162.26%
7.25USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC is a globally operating pharmaceutical company with its headquarters in England. The company was founded in 1999 through the merger of the Swedish company Astra AB and the British Zeneca Group PLC. Today, AstraZeneca employs more than 70,000 people and operates in over 100 countries. AstraZeneca specializes in the development, manufacturing, and marketing of pharmaceutical products. The company focuses primarily on oncology, cardiovascular and metabolic diseases, respiratory diseases, and autoimmune diseases. AstraZeneca is divided into various business segments. The oncology segment is a major focus of the company. Here, medications for various types of cancer are developed and manufactured. One particularly well-known product is the breast cancer medication Tamoxifen. In the cardiovascular and metabolic diseases segment, AstraZeneca offers various medications for heart and circulatory diseases as well as diabetes. One of the most well-known medications is Crestor, which is used to lower cholesterol levels. Another important area for AstraZeneca is respiratory diseases. Medications for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are developed and manufactured here. The medication Pulmicort is particularly well-known among asthma patients. Finally, AstraZeneca is also active in the field of autoimmune diseases. Medications against lupus erythematosus and rheumatoid arthritis are developed and manufactured here. AstraZeneca strives to improve healthcare worldwide through research and development of new medications. The company works closely with universities and research institutions and invests billions of dollars annually in research and development. AstraZeneca also pursues a sustainable business strategy and emphasizes acting environmentally and socially responsibly. The company is committed to reducing CO2 emissions and minimizing waste production. Over the years, AstraZeneca has received numerous awards and prizes, including the Sunday Times Innovation Award of the Decade, the Fierce Biotech Award for the medication Tagrisso, and the Prix Galien USA Award for Crestor. AstraZeneca aims to develop innovative medications that improve the lives of patients and advance healthcare worldwide. The company believes in a sustainable business strategy and actively promotes environmental and social responsibility. AstraZeneca will remain an important player in the global pharmaceutical industry in the future. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

Tangible Book Value per Share of AstraZeneca is -6.67 USD in 2025.

Tangible Book Value per Share of AstraZeneca changed from -11.15 USD to -6.67 USD, representing a -40.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AstraZeneca

All Key Metrics — AstraZeneca